Testing a drug combination with focused radiation for melanoma that spread to the brain
Official title: Bevacizumab and ICIs + hSRT in Symptomatic Melanoma Brain Metastases
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on .
The short version
This study tests three cancer drugs together with focused radiation for melanoma brain tumors.
Read our full plain-language summary
What the trial team says
Single arm phase I/II trial to evaluate the safety and efficacy of the combination of bevacizumab, with ipilimumab plus nivolumab, and hypofractionated stereotactic radiotherapy (hSRT) in patients with symptomatic melanoma brain metastases (MBM).
Key facts
- Registry number
- NCT06163820
- Stage of testing
- Phase 1/Phase 2
- Conditions studied
- Melanoma Brain Metastases
Where it is running
This trial lists 1 site.
-
Victoria
- Alfred Health (Melbourne)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.